MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board
MindMed (NASDAQ: MNMD) (NEO: MMED), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the appointment of Maria A. Oquendo, M.D., Ph.D. to its Scientific Advisory Board.
Dr. Oquendo is Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania and Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania. A summa cum laude graduate of Tufts University, she attended Vagelos College of Physicians and Surgeons at Columbia University. She completed residency at the Payne Whitney Clinic of New York Hospital Cornell. She is a member of the National Academy of Medicine, one of the highest honors in medicine.
Dr. Oquendo has used Positron Emission Tomography and Magnetic Resonance Imaging to map brain abnormalities related to mood disorders and suicidal behavior. She has over 450 peer-reviewed publications and an h-factor of 78, with over 18,000 citations.
Dr. Oquendo is Past President of the American Psychiatric Association (APA), the International Academy of Suicide Research, and the American College of Neuropsychopharmacology (ACNP). She is Vice President of the Board of the American Foundation for Suicide Prevention, Vice President of the College of International Neuropsychopharmacology, and has served on the National Institute of Mental Health’s Advisory Council.
Dr. Oquendo is a member of Tufts University’s Board of Trustees and serves on its Executive Committee. A recipient of multiple awards in the US, Europe and South America, most recently, she was honored with the Alexandra Symonds Award (APA 2017), the APA’s Research Award (2018), the Dolores Shockley Award (ACNP 2018) and the Alexander Glassman Award (Columbia University 2021).
We are thrilled to welcome Dr. Oquendo to our Scientific Advisory Board. Our goal is to revolutionize mental health and addiction care and we want to make effective treatments accessible to broad and diverse patient populations from across the globe. Dr. Oquendo’s extensive experience in psychiatry and pharmacology, including her work with high risk patients, will be invaluable in progressing all of our research and development efforts.
MindMed CEO Robert Barrow
Dr. Oquendo added, “In view of the pharmacologic actions that compounds like LSD and psilocybin share with putative anti-suicidal drugs, this exciting avenue of investigation may lead to discoveries of new approaches to this life-threatening behavior.”
MindMed’s Scientific Advisory Board is composed of a diverse group of members with expertise in psychiatry, neuroscience, and clinical development. The Scientific Advisory Board leverages decades of deep knowledge in biotech and psychiatry to guide MindMed’s development programs. Members represent institutions such as Stanford University, University of Pennsylvania, University of Rochester, Boston University, and Massachusetts General Hospital.
To view the original press release in its entirety click here
